Frequently Asked Questions (FAQs)

Learn more about ongoing clinical trials evaluating investigational compounds to improve and expand treatments for patients with inflammatory and autoimmune conditions, such as Hidradenitis Suppurativa and Prurigo Nodularis.

Match to a Trial

Join the Incyte Community

Join the Incyte Community to receive updates on news about Incyte, including information on newly enrolling trials. The Incyte Community enables you to stay informed & prepared to contribute to research you care about.

Join Incyte Community

About IAI

Incyte’s research and development efforts in Dermatology are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to develop treatments that restore normal immune function to the body. Many inflammatory conditions such as Hidradenitis Suppurativa (HS) and Pruirgo Nodularis (PN) are affected by a dysregulation of the JANUS kinase (JAK)/ signal transducer and activator of transcription (STAT) pathway.

Currently, Incyte is exploring the potential of JAK inhibition for additional indications with a high unmet medical need that results from an abnormal immune system response, such as HS and PN.

We strive to identify and develop therapies to stop uncontrolled inflammation, help restore normal immune function, and bring the body closer to equilibrium.

Match to a trial

Hidradentis Suppurtiva

Hidradenitis suppurativa (HS) is a long-term skin condition that causes painful bumps, boils and/or abscesses to develop under the skin. It usually develops in areas where there is hair or where the skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts. People with HS can have repeated outbreaks of HS, which can leave scars on the skin. As HS gets more severe, these bumps, boils and/or abscesses can rupture or leak and cause scarring.

Researchers are looking for other ways to treat HS. In these trials, researchers are studying an investigational drug called “povorcitinib”, which is a JAK1 inhibitor taken by mouth.  JAK1 inhibitors are a type of medication that interfere with signals of the body that are thought to cause inflammation. This, in turn, reduces the inflammation that is linked with HS; with less inflammation, symptoms of your HS such as pain, discharge, and itch are also reduced, and your HS lesions are expected to get better.  


Prurigo nodularis (PN) is a long-term skin condition that causes itchy bumps called “nodules” on the skin. These nodules can appear in any part of the body, but most often appear in areas where you can scratch, such as the arms, legs, and trunk. Aside from severe itching, people with PN may also feel painful stinging and burning. These symptoms can affect a person’s quality of life.

In these trials, researchers are investigating the use of the JAK inhibitor, ruxolitinib cream for the (topical) treatment of PN to determine if it is effective in relieving itch and healing the nodules.